As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
